Par Pharmaceutical Generics Company Intelligence Report

Date: January 22, 2011
Pages: 20
Price:
US$ 340.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PD756F90EFAEN
Leaflet:

Download PDF Leaflet

Par Pharmaceutical Generics Company Intelligence Report
Par Pharmaceutical was founded in New York in 1978. The company develops, manufactures, and markets generic drugs and innovative branded pharmaceuticals for
specialty markets.

Many products are licensed-in from other generic manufacturers or originator companies. Par has concluded a number of authorised generic agreements with originators. Of particular benefit has been an authorised generic agreement with AstraZeneca for metoprolol succinate. Other agreements have been signed with Bristol-Myers Squibb and GlaxoSmithKline.

Par’s products are sold either as generics or branded products. The firm’s generic product line consists of some 50 products. Par’s branded segment operates under the name Strativa Pharmaceuticals.

Sales in 2009 were worth US$1,193.2 million, more than double the firm's sales result for 2008. Generics accounted for US$1,104.3 million of this, rising by 125% over 2008. The increase was partly the result of a dip in sales in 2009, coupled with increases in sales of products such as metoprolol.

EXECUTIVE SUMMARY

INTRODUCTION

PRODUCTS

Par Pharmaceutical Companies: generic drugs sold in 2009
Strativa provides proprietary ondansetron product update
Par Pharmaceutical ANDA Approvals, January 2002 – September 2010
Kali Laboratories ANDA Approvals, January 2004 – September 2010
Recent Product Approvals
Zafirlukast (authorised generic)
Omeprazole / sodium bicarbonate
Ondansetron
Miconazole
Tramadol
Nateglinide
Transdermal clonidine

FINANCIAL RESULTS

Latest Quarterly Revenues, Q310
Par Pharmaceutical Companies: quarterly results, in US$000s
Latest Fiscal Year Results, FY09
Par Pharmaceutical Companies: Fiscal Year Results, in US$000s
Segment Data
Par Pharmaceutical Companies: Fiscal Year Results by Segment, in US$000s
Par Pharmaceutical Companies: Top Selling PRODUCTS
, in US$000s

MAJOR DEVELOPMENTS

Mergers, acquisitions and agreements
Par enters ezetimibe agreement with Glenmark; Glenmark settles litigation with Merck
Alvogen acquires R&D capabilities from Par
Litigation
Pronova files suits against Par and Teva regarding omega-3-acid ethyl esters
Par challenges mesalamine patents
Rosuvastatin patent upheld in court
Appellate court upholds tramadol decision in Par's favour
IntelliPharmaCeutics and Par settle dexmethylphenidate litigation with Novartis
Par sees victory in omeprazole / sodium bicarbonate litigation
sanofi-aventis enters into a series of oxaliplatin patent settlements
IntelliPharmaCeutics settles dexmethylphenidate lawsuit with Novartis, Celgene and Elan
Par sees success in tramadol ER litigation

CONTACT DETAILS
Skip to top


Ask Your Question

Par Pharmaceutical Generics Company Intelligence Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: